The Latest Breaking News from Penumbra

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

Upgrades

Pulled from Benzinga Pro data, Penumbra (NYSE:PEN) posted Q1 earnings of $79.00 thousand, an increase from Q4 of 100.32%. Sales dropped to $203.90 million, a 0.06% decrease between quarters.

Analysts have provided the following ratings for Penumbra (NYSE:PEN) within the last quarter:

Penumbra (NYSE:PEN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra missed estimated earnings by 116.67%, reporting an EPS of $-0.01 versus an estimate of $0.06.

Upgrades

Penumbra Inc (NYSE:PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (31.1%) to $113.6 million.  Revenue from sales of neuro products grew 13.3% (14.1%) to $90.4 million. The gross margin was 61.5%,…

Benzinga Pro data, Penumbra (NYSE:PEN) reported Q4 sales of $204.01 million. Earnings fell to a loss of $24.63 million, resulting in a 406.72% decrease from last quarter. In Q3, Penumbra earned $8.03 million and total sales reached $190.12 million.